Resultados da pesquisa - Márk Barok

  • A mostrar 1 - 10 resultados de 10
Refinar resultados
  1. 1
    Trastuzumab emtansine: mechanisms of action and drug resistance

    Trastuzumab emtansine: mechanisms of action and drug resistance Por Márk Barok, Heikki Joensuu, Jorma Isola

    Publicado em 2014
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  2. 2
    Die hard: Are cancer stem cells the Bruce Willises of tumor biology?

    Die hard: Are cancer stem cells the Bruce Willises of tumor biology? Por Ákos Fábián, Márk Barok, György Vereb, János Szöllősi

    Publicado em 2008
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  3. 3
    Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo

    Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo Por Márk Barok, Minna Tanner, Katri Köninki, Jorma Isola

    Publicado em 2011
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  4. 4
    Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation

    Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation Por Márk Barok, Maija Puhka, György Vereb, János Szöllősi, Jorma Isola, Heikki Joensuu

    Publicado em 2018
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  5. 5
    Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer

    Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer Por Zsuzsanna Pályi‐Krekk, Márk Barok, Jorma Isola, Markku Tammi, János Szöllo ̋si, Péter Nagy

    Publicado em 2007
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  6. 6
    A Novel Anti-HER2 Antibody–Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine

    A Novel Anti-HER2 Antibody–Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine Por Vadim Le Joncour, Ana Martins, Maija Puhka, Jorma Isola, Marko Salmikangas, Pirjo Laakkonen, Heikki Joensuu, Márk Barok

    Publicado em 2019
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  7. 7
    Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model

    Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model Por Negar Pourjamal, Narjes Yazdi, A. Halme, Vadim Le Joncour, Pirjo Laakkonen, Pipsa Saharinen, Heikki Joensuu, Márk Barok

    Publicado em 2024
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  8. 8
    Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan

    Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan Por Negar Pourjamal, Vadim Le Joncour, György Vereb, Cilla Honkamäki, Jorma Isola, Jeffrey V. Leyton, Pirjo Laakkonen, Heikki Joensuu, Márk Barok

    Publicado em 2025
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  9. 9
    EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis

    EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis Por Zsuzsa Rákosy, Laura Vízkeleti, Szilvia Ecsedi, Zoltán Vokó, Ágnes Bégány, Márk Barok, Zsuzsa Krekk, Mónika Gallai, Zoltán Szentirmay, Róza Ádány, Margit Balázs

    Publicado em 2007
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  10. 10
    Trastuzumab causes antibody-dependent cellular cytotoxicity–mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance

    Trastuzumab causes antibody-dependent cellular cytotoxicity–mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance Por Márk Barok, Jorma Isola, Zsuzsanna Pályi‐Krekk, Péter Nagy, István Juhász, György Vereb, Päivikki Kauraniemi, Anita Kapanen, Minna Tanner, György Vereb, János Szöllősi

    Publicado em 2007
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:

Ferramentas de pesquisa: